MovDisordV3, Main, Exploration, bibRecord, 002578

The nociceptin/orphanin FQ (NOP) receptor antagonist J‐113397 enhances the effects of levodopa in the MPTP‐lesioned nonhuman primate model of Parkinson's disease

Identifieur interne : 002578 ( Main/Exploration ); précédent : 002577; suivant : 002579

The nociceptin/orphanin FQ (NOP) receptor antagonist J‐113397 enhances the effects of levodopa in the MPTP‐lesioned nonhuman primate model of Parkinson's disease

Auteurs : Naomi P. Visanji [Canada] ; Rob M. A. De Bie [Canada, Pays-Bas] ; Tom H. Johnston [Canada] ; Andrew C. Mccreary [Pays-Bas] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada]

Source :

Movement Disorders [ 0885-3185 ] ; 2008-10-15.

RBID : ISTEX:94F291E4B0C8056170DA9F7765D5C13E4056C439

Descripteurs français

Pascal (Inist)
- Dyskinésie, Lévodopa, Maladie de Parkinson, Modèle, Nociceptine, Pathologie du système nerveux, Primates, Récepteur N/OFQ.

English descriptors

KwdEn :
- Analysis of Variance, Animals, Antiparkinson Agents (therapeutic use), Benzimidazoles (therapeutic use), Callithrix, Disability Evaluation, Disease Models, Animal, Drug Synergism, Dyskinesia, Levodopa, Levodopa (therapeutic use), MPTP, MPTP Poisoning (drug therapy), Models, N/OFQ receptor, Nervous system diseases, Nociceptin, Opioid Peptides (antagonists & inhibitors), Parkinson disease, Piperidines (therapeutic use), Primates, Time Factors, dyskinesia, levodopa, marmoset, nociceptin/orphanin FQ.
MESH :
- chemical , antagonists & inhibitors : Opioid Peptides.
- chemical , therapeutic use : Antiparkinson Agents, Benzimidazoles, Levodopa, Piperidines.
- drug therapy : MPTP Poisoning.
- Analysis of Variance, Animals, Callithrix, Disability Evaluation, Disease Models, Animal, Drug Synergism, Time Factors.

Abstract

The anti‐parkinsonian and levodopa‐sparing potential of the nociceptin/orphanin FQ receptor (NOP) antagonist J‐113397 has been demonstrated in rodent models of Parkinson's disease. Here, we describe the levodopa‐sparing potential of J‐113397 in MPTP‐lesioned marmosets. Coadministration of J‐113397 (30 mg/kg) with a sub‐therapeutic dose of levodopa (12.5 mg/kg) produced an anti‐parkinsonian action equivalent to that of a therapeutic dose of levodopa. However, these effects were accompanied by an equivalent level of dyskinesia. The actions of NOP antagonists seen in rodents translate to nonhuman primates. However, the present study raises the possibility that these levodopa‐sparing benefits may be offset by a propensity to exacerbate dyskinesia. © 2008 Movement Disorder Society

Url:

https://api.istex.fr/document/94F291E4B0C8056170DA9F7765D5C13E4056C439/fulltext/pdf

DOI: 10.1002/mds.22086

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The nociceptin/orphanin FQ (NOP) receptor antagonist J‐113397 enhances the effects of levodopa in the MPTP‐lesioned nonhuman primate model of Parkinson's disease</title>
<author><name sortKey="Visanji, Naomi P" sort="Visanji, Naomi P" uniqKey="Visanji N" first="Naomi P." last="Visanji">Naomi P. Visanji</name>
</author>
<author><name sortKey="De Bie, Rob M A" sort="De Bie, Rob M A" uniqKey="De Bie R" first="Rob M. A." last="De Bie">Rob M. A. De Bie</name>
</author>
<author><name sortKey="Johnston, Tom H" sort="Johnston, Tom H" uniqKey="Johnston T" first="Tom H." last="Johnston">Tom H. Johnston</name>
</author>
<author><name sortKey="Mccreary, Andrew C" sort="Mccreary, Andrew C" uniqKey="Mccreary A" first="Andrew C." last="Mccreary">Andrew C. Mccreary</name>
</author>
<author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
</author>
<author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:94F291E4B0C8056170DA9F7765D5C13E4056C439</idno>
<date when="2008" year="2008">2008</date>
<idno type="doi">10.1002/mds.22086</idno>
<idno type="url">https://api.istex.fr/document/94F291E4B0C8056170DA9F7765D5C13E4056C439/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001416</idno>
<idno type="wicri:Area/Istex/Curation">001416</idno>
<idno type="wicri:Area/Istex/Checkpoint">001134</idno>
<idno type="wicri:doubleKey">0885-3185:2008:Visanji N:the:nociceptin:orphanin</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:18759357</idno>
<idno type="wicri:Area/PubMed/Corpus">002071</idno>
<idno type="wicri:Area/PubMed/Curation">002071</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002034</idno>
<idno type="wicri:Area/Ncbi/Merge">002292</idno>
<idno type="wicri:Area/Ncbi/Curation">002292</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002292</idno>
<idno type="wicri:Area/Main/Merge">003156</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:08-0522213</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001077</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001C42</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001054</idno>
<idno type="wicri:doubleKey">0885-3185:2008:Visanji N:the:nociceptin:orphanin</idno>
<idno type="wicri:Area/Main/Merge">003662</idno>
<idno type="wicri:Area/Main/Curation">002578</idno>
<idno type="wicri:Area/Main/Exploration">002578</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The nociceptin/orphanin FQ (NOP) receptor antagonist J‐113397 enhances the effects of levodopa in the MPTP‐lesioned nonhuman primate model of Parkinson's disease</title>
<author><name sortKey="Visanji, Naomi P" sort="Visanji, Naomi P" uniqKey="Visanji N" first="Naomi P." last="Visanji">Naomi P. Visanji</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Toronto Western Research Institute, Toronto</wicri:regionArea>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="De Bie, Rob M A" sort="De Bie, Rob M A" uniqKey="De Bie R" first="Rob M. A." last="De Bie">Rob M. A. De Bie</name>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Neurology, University of Toronto, Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Current Address: Department of Neurology, Academic Medical Center, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Johnston, Tom H" sort="Johnston, Tom H" uniqKey="Johnston T" first="Tom H." last="Johnston">Tom H. Johnston</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Toronto Western Research Institute, Toronto</wicri:regionArea>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mccreary, Andrew C" sort="Mccreary, Andrew C" uniqKey="Mccreary A" first="Andrew C." last="Mccreary">Andrew C. Mccreary</name>
<affiliation wicri:level="1"><country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Solvay Pharmaceuticals Research Laboratories, Weesp</wicri:regionArea>
<wicri:noRegion>Weesp</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Toronto Western Research Institute, Toronto</wicri:regionArea>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Toronto Western Research Institute, Toronto</wicri:regionArea>
<wicri:noRegion>Toronto</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Neurology, University of Toronto, Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2008-10-15">2008-10-15</date>
<biblScope unit="vol">23</biblScope>
<biblScope unit="issue">13</biblScope>
<biblScope unit="page" from="1922">1922</biblScope>
<biblScope unit="page" to="1925">1925</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">94F291E4B0C8056170DA9F7765D5C13E4056C439</idno>
<idno type="DOI">10.1002/mds.22086</idno>
<idno type="ArticleID">MDS22086</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Analysis of Variance</term>
<term>Animals</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Benzimidazoles (therapeutic use)</term>
<term>Callithrix</term>
<term>Disability Evaluation</term>
<term>Disease Models, Animal</term>
<term>Drug Synergism</term>
<term>Dyskinesia</term>
<term>Levodopa</term>
<term>Levodopa (therapeutic use)</term>
<term>MPTP</term>
<term>MPTP Poisoning (drug therapy)</term>
<term>Models</term>
<term>N/OFQ receptor</term>
<term>Nervous system diseases</term>
<term>Nociceptin</term>
<term>Opioid Peptides (antagonists & inhibitors)</term>
<term>Parkinson disease</term>
<term>Piperidines (therapeutic use)</term>
<term>Primates</term>
<term>Time Factors</term>
<term>dyskinesia</term>
<term>levodopa</term>
<term>marmoset</term>
<term>nociceptin/orphanin FQ</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Opioid Peptides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Benzimidazoles</term>
<term>Levodopa</term>
<term>Piperidines</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>MPTP Poisoning</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Analysis of Variance</term>
<term>Animals</term>
<term>Callithrix</term>
<term>Disability Evaluation</term>
<term>Disease Models, Animal</term>
<term>Drug Synergism</term>
<term>Time Factors</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Dyskinésie</term>
<term>Lévodopa</term>
<term>Maladie de Parkinson</term>
<term>Modèle</term>
<term>Nociceptine</term>
<term>Pathologie du   système nerveux</term>
<term>Primates</term>
<term>Récepteur N/OFQ</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The anti‐parkinsonian and levodopa‐sparing potential of the nociceptin/orphanin FQ receptor (NOP) antagonist J‐113397 has been demonstrated in rodent models of Parkinson's disease. Here, we describe the levodopa‐sparing potential of J‐113397 in MPTP‐lesioned marmosets. Coadministration of J‐113397 (30 mg/kg) with a sub‐therapeutic dose of levodopa (12.5 mg/kg) produced an anti‐parkinsonian action equivalent to that of a therapeutic dose of levodopa. However, these effects were accompanied by an equivalent level of dyskinesia. The actions of NOP antagonists seen in rodents translate to nonhuman primates. However, the present study raises the possibility that these levodopa‐sparing benefits may be offset by a propensity to exacerbate dyskinesia. © 2008 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
<li>Pays-Bas</li>
</country>
<region><li>Hollande-Septentrionale</li>
<li>Ontario</li>
</region>
<settlement><li>Amsterdam</li>
<li>Toronto</li>
</settlement>
<orgName><li>Université de Toronto</li>
</orgName>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Visanji, Naomi P" sort="Visanji, Naomi P" uniqKey="Visanji N" first="Naomi P." last="Visanji">Naomi P. Visanji</name>
</noRegion>
<name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
<name sortKey="De Bie, Rob M A" sort="De Bie, Rob M A" uniqKey="De Bie R" first="Rob M. A." last="De Bie">Rob M. A. De Bie</name>
<name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
<name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
<name sortKey="Johnston, Tom H" sort="Johnston, Tom H" uniqKey="Johnston T" first="Tom H." last="Johnston">Tom H. Johnston</name>
</country>
<country name="Pays-Bas"><region name="Hollande-Septentrionale"><name sortKey="De Bie, Rob M A" sort="De Bie, Rob M A" uniqKey="De Bie R" first="Rob M. A." last="De Bie">Rob M. A. De Bie</name>
</region>
<name sortKey="Mccreary, Andrew C" sort="Mccreary, Andrew C" uniqKey="Mccreary A" first="Andrew C." last="Mccreary">Andrew C. Mccreary</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002578 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002578 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:94F291E4B0C8056170DA9F7765D5C13E4056C439
   |texte=   The nociceptin/orphanin FQ (NOP) receptor antagonist J‐113397 enhances the effects of levodopa in the MPTP‐lesioned nonhuman primate model of Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

The nociceptin/orphanin FQ (NOP) receptor antagonist J‐113397 enhances the effects of levodopa in the MPTP‐lesioned nonhuman primate model of Parkinson's disease

The nociceptin/orphanin FQ (NOP) receptor antagonist J‐113397 enhances the effects of levodopa in the MPTP‐lesioned nonhuman primate model of Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.